Countdown to the Finals of the ASC24 Student Supercomputer Challenge!
The 2024 ASC Student Supercomputer Challenge (ASC24) finals are scheduled to take place at Shanghai University from April 9 to 13, 2024. Among the over 300 teams representing universities worldwide, only 25 have progressed to the finals. Throughout the competition finals, teams will face a series of challenges including optimizing large language model (LLM) inference, tackling tasks like OpenCAEPoro and GoMars, as well as competing in high-performance benchmarks such as HPL and HPCG. Additionally, teams will engage in group competitions and tackle a mystery application. Each team will present their projects before the jury, contending for prestigious awards including the Champion, Silver Prize, e Prize, and the Highest LINPACK.
The ASC24 Student Supercomputer Challenge Finals
|
Date |
Time |
Agenda |
|
April 9 |
08:00-20:00 |
Rule Announcement, Cluster Setup/Testing |
|
April 10 |
08:00-20:00 |
Cluster Setup/Testing |
|
April 11 |
08:00-18:00 |
Competition: HPL & HPCG, Group Competition, LLM |
|
April 12 |
08:00-18:00 |
Competition: OpenCAEPoro, GoMars, mystery APP |
|
14:00-17:00 |
The 33rd HPC Connection Workshop |
|
|
April 13 |
08:00-12:10 |
Finalist Teams Presentations before the Jury |
|
15:00-17:30 |
Closing and awards ceremony |
ASC is committed to assisting students in addressing state-of-the-art scientific challenges through the utilization of the most advanced computing products and technologies. This endeavor aims to explore emerging research paradigms and confront the various challenges humanity faces. The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.
The prestigious e Prize will be bestowed upon the winners of the OpenCAEPoro task, which entails simulating the seepage of multiphase fluids, such as oil, gas, and water, particularly within contexts relevant to petroleum extraction. Competitors are tasked with skillfully optimizing large-scale parallel computing processes, emphasizing enhancements in computing performance and parallel efficiency of discrete algorithms.
In the GoMars task, participating teams are challenged with optimizing parallel communication and refining computational load balancing within the dynamic framework of GoMars. GoMars represents a new generation of Mars atmosphere models. The objective is to enhance operational efficiency and achieve more precise predictions of the Martian atmosphere.
In the LLM Inference Optimization Challenge, participating teams are assigned the task of constructing and refining inference engines utilizing the widely employed open-source LLM, AquilaChat2-34B. The primary objective is to expedite inference processes by employing 4-bit or less quantization while maintaining overall accuracy.
Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students. Students will be randomly allocated to one of five groups. Each group will work collectively on the ParaSeis task, employing ParaSeis to simulate seismic wave propagation and refine the algorithm through collaborative communication. The group's performance will be evaluated based on the average score of its constituent teams, with the group achieving the highest score declared as the victor.
The finals will bring together formidable teams from renowned universities, including Peking University - the champion of the 10th ASC onsite finals, the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals, University of Science and Technology of China, Huazhong University of Science and Technology, Shanghai Jiao Tong University, and Friedrich-Alexander-University Erlangen-Nuremberg.
Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them. Excitement surrounds the debut of teams from the National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, making their inaugural ASC finals appearance this year. The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.
About ASC
The ASC Student Supercomputer Challenge is the world's largest student supercomputer competition, sponsored and organized by the Asia Supercomputer Community with support from experts and institutions across Asia, Europe, and America. The main objectives of ASC are to encourage the exchange and training of young supercomputing talent from different countries, improve supercomputing applications and R&D capacity, boost the development of supercomputing, and promote technical and industrial innovation. The first ASC Student Supercomputer Challenge was held in 2012 and has since attracted over 10,000 undergraduates from all over the world. Learn more for ASC at http://www.asc-events.net/StudentChallenge/index.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402763009/en/
Contact information
Media
media@asc-events.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
